220 related articles for article (PubMed ID: 18182994)
1. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Mitra A; Fisher C; Foster CS; Jameson C; Barbachanno Y; Bartlett J; Bancroft E; Doherty R; Kote-Jarai Z; Peock S; Easton D; ; Eeles R
Br J Cancer; 2008 Jan; 98(2):502-7. PubMed ID: 18182994
[TBL] [Abstract][Full Text] [Related]
2. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
[TBL] [Abstract][Full Text] [Related]
3. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
[TBL] [Abstract][Full Text] [Related]
5. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
[TBL] [Abstract][Full Text] [Related]
7. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
[TBL] [Abstract][Full Text] [Related]
8. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
9. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
10. Association of Genomic Domains in
Patel VL; Busch EL; Friebel TM; Cronin A; Leslie G; McGuffog L; Adlard J; Agata S; Agnarsson BA; Ahmed M; Aittomäki K; Alducci E; Andrulis IL; Arason A; Arnold N; Artioli G; Arver B; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barnes DR; Barroso A; Barrowdale D; Belotti M; Benitez J; Bertelsen B; Blok MJ; Bodrogi I; Bonadona V; Bonanni B; Bondavalli D; Boonen SE; Borde J; Borg A; Bradbury AR; Brady A; Brewer C; Brunet J; Buecher B; Buys SS; Cabezas-Camarero S; Caldés T; Caliebe A; Caligo MA; Calvello M; Campbell IG; Carnevali I; Carrasco E; Chan TL; Chu ATW; Chung WK; Claes KBM; Collaborators GS; Collaborators E; Cook J; Cortesi L; Couch FJ; Daly MB; Damante G; Darder E; Davidson R; de la Hoya M; Puppa LD; Dennis J; Díez O; Ding YC; Ditsch N; Domchek SM; Donaldson A; Dworniczak B; Easton DF; Eccles DM; Eeles RA; Ehrencrona H; Ejlertsen B; Engel C; Evans DG; Faivre L; Faust U; Feliubadaló L; Foretova L; Fostira F; Fountzilas G; Frost D; García-Barberán V; Garre P; Gauthier-Villars M; Géczi L; Gehrig A; Gerdes AM; Gesta P; Giannini G; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gutierrez-Barrera AM; Hahnen E; Hamann U; Hauke J; Herold N; Hogervorst FBL; Honisch E; Hopper JL; Hulick PJ; Investigators K; Investigators H; Izatt L; Jager A; James P; Janavicius R; Jensen UB; Jensen TD; Johannsson OT; John EM; Joseph V; Kang E; Kast K; Kiiski JI; Kim SW; Kim Z; Ko KP; Konstantopoulou I; Kramer G; Krogh L; Kruse TA; Kwong A; Larsen M; Lasset C; Lautrup C; Lazaro C; Lee J; Lee JW; Lee MH; Lemke J; Lesueur F; Liljegren A; Lindblom A; Llovet P; Lopez-Fernández A; Lopez-Perolio I; Lorca V; Loud JT; Ma ESK; Mai PL; Manoukian S; Mari V; Martin L; Matricardi L; Mebirouk N; Medici V; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller C; Gomes DM; Montagna M; Mooij TM; Moserle L; Mouret-Fourme E; Mulligan AM; Nathanson KL; Navratilova M; Nevanlinna H; Niederacher D; Nielsen FCC; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Ong KR; Osorio A; Ott CE; Palli D; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Pérez-Segura P; Peterlongo P; Petersen AH; Porteous ME; Pujana MA; Radice P; Ramser J; Rantala J; Rashid MU; Rhiem K; Rizzolo P; Robson ME; Rookus MA; Rossing CM; Ruddy KJ; Santos C; Saule C; Scarpitta R; Schmutzler RK; Schuster H; Senter L; Seynaeve CM; Shah PD; Sharma P; Shin VY; Silvestri V; Simard J; Singer CF; Skytte AB; Snape K; Solano AR; Soucy P; Southey MC; Spurdle AB; Steele L; Steinemann D; Stoppa-Lyonnet D; Stradella A; Sunde L; Sutter C; Tan YY; Teixeira MR; Teo SH; Thomassen M; Tibiletti MG; Tischkowitz M; Tognazzo S; Toland AE; Tommasi S; Torres D; Toss A; Trainer AH; Tung N; van Asperen CJ; van der Baan FH; van der Kolk LE; van der Luijt RB; van Hest LP; Varesco L; Varon-Mateeva R; Viel A; Vierstraete J; Villa R; von Wachenfeldt A; Wagner P; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Wieme G; Yadav S; Yannoukakos D; Yoon SY; Zanzottera C; Zorn KK; D'Amico AV; Freedman ML; Pomerantz MM; Chenevix-Trench G; Antoniou AC; Neuhausen SL; Ottini L; Nielsen HR; Rebbeck TR
Cancer Res; 2020 Feb; 80(3):624-638. PubMed ID: 31723001
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
[TBL] [Abstract][Full Text] [Related]
13. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
[TBL] [Abstract][Full Text] [Related]
14. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
Horsburgh S; Matthew A; Bristow R; Trachtenberg J
Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
[TBL] [Abstract][Full Text] [Related]
16. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract][Full Text] [Related]
17. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract][Full Text] [Related]
18. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
19. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Hutten Selkirk C; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; ; ; Eeles RA; Aaronson NK
BJU Int; 2019 Feb; 123(2):284-292. PubMed ID: 29802810
[TBL] [Abstract][Full Text] [Related]
20. Rapid progression of prostate cancer in men with a BRCA2 mutation.
Narod SA; Neuhausen S; Vichodez G; Armel S; Lynch HT; Ghadirian P; Cummings S; Olopade O; Stoppa-Lyonnet D; Couch F; Wagner T; Warner E; Foulkes WD; Saal H; Weitzel J; Tulman A; Poll A; Nam R; Sun P; ; Danquah J; Domchek S; Tung N; Ainsworth P; Horsman D; Kim-Sing C; Maugard C; Eisen A; Daly M; McKinnon W; Wood M; Isaacs C; Gilchrist D; Karlan B; Nedelcu R; Meschino W; Garber J; Pasini B; Manoukian S; Bellati C
Br J Cancer; 2008 Jul; 99(2):371-4. PubMed ID: 18577985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
